Article
Medicine, General & Internal
Marco Rubatto, Franco Picciotto, Giovenale Moirano, Enrico Fruttero, Virginia Caliendo, Silvia Borriello, Nadia Sciamarrelli, Paolo Fava, Rebecca Senetta, Adriana Lesca, Anna Sapino, Desiree Deandreis, Simone Ribero, Pietro Quaglino
Summary: This study evaluated the characteristics of patients with head and neck melanoma who underwent sentinel lymph node biopsy and found that scalp melanomas are more aggressive than non-scalp melanomas. The status of the sentinel lymph node is the strongest predictor for recurrence.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Franco Picciotto, Gianluca Avallone, Federico Castellengo, Martina Merli, Virginia Caliendo, Rebecca Senetta, Adriana Lesca, Desiree Deandreis, Maria Teresa Fierro, Pietro Quaglino, Simone Ribero
Summary: Sentinel lymph node biopsy is an effective staging procedure, but the current classification may result in inaccurate staging. A new surgical technique combined with SPECT-CT can better guide surgeons to improve staging accuracy for melanoma patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Dermatology
Adrienne B. Shannon, Cimarron E. Sharon, Richard J. Straker, Michael J. Carr, Andrew J. Sinnamon, Kita Bogatch, Alexandra Thaler, Nicholas Kelly, John T. Vetto, Graham Fowler, Danielle DePalo, Vernon K. Sondak, John T. Miura, Mark B. Faries, Edmund K. Bartlett, Jonathan S. Zager, Giorgos C. Karakousis
Summary: Sentinel lymph node biopsy is not routinely recommended for T1a cutaneous melanoma due to low risk of positivity. This study identified age, primary tumor location, lymphovascular invasion, and mitotic rate as factors associated with positive sentinel lymph node in T1a melanoma patients.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Isong Assam, Simon P. Dierck, Yi Zhao, Michael Jueptner, Frank-Andre Siebert, Maaz Zuhayra, Ulf Luetzen
Summary: The handheld gamma-camera CrystalCam, based on high-resolution semiconductor detectors, was evaluated for localizing sentinel lymph nodes (SLN) using phantom and clinical studies. The results showed that CrystalCam has similar accuracy to conventional planar lymphoscintigraphy in detecting SLNs in malignant melanoma, but is inferior in detecting higher-echelon nodes compared to planar imaging.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2023)
Article
Medicine, General & Internal
James R. Miller, Serigne N. Lo, Mehdi Nosrati, Jonathan R. Stretch, Andrew J. Spillane, Robyn P. M. Saw, Kerwin F. Shannon, Omgo E. Nieweg, Sydney Ch'ng, Kevin B. Kim, Stanley P. Leong, John F. Thompson, Richard A. Scolyer, Mohammed Kashani-Sabet
Summary: By refining eligibility guidelines, more appropriate patients can be identified to undergo useful medical procedures, improving cost-effectiveness in selecting patients with melanoma for sentinel lymph node biopsy (SLNB).
Article
Oncology
Taylor J. Aiken, Christopher C. Stahl, Patrick B. Schwartz, James Barrett, Alexandra W. Acher, Deborah Lemaster, Glen Leverson, Sharon Weber, Heather Neuman, Daniel E. Abbott
Summary: In patients with higher risk thin melanoma, SLNB is associated with increased costs despite a low likelihood of SLN positivity. These data help to better inform patient-provider discussions as the role of SLNB in thin melanoma evolves.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Dermatology
Viengneesee Thao, Ruchita Dholakia, James P. Moriarty, Bijan J. Borah, Jvalini Dwarkasing, Alexander Meves
Summary: This study compared the cost of using the Merlin assay for melanoma-risk assessment to that of a no-testing strategy before performing sentinel lymph node biopsies. The findings suggest that Merlin testing may be cost saving and improve health-related quality of life in certain cases.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Julia Huynh, Ulrike Leiter, Claus Garbe, Galina Shiderova, Vincent Walter, Thomas Eigentler, Alexander Scheu, Hans-Martin Haefner, Saskia Maria Schnabl
Summary: This study investigated the use of sentinel lymph node biopsy in patients with lentigo maligna melanoma and tumor thickness ≥1 mm. The results showed that sentinel lymph nodes were positive in 12.7% of cases. There was no significant difference in distant metastasis-free survival and overall survival between patients with and without sentinel lymph node biopsy.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Liming Xiao, Shupeng Yu, Weina Xu, Yishan Sun, Jun Xin
Summary: Tc-99m-3PRGD(2) SPECT/CT imaging performs well in diagnosing lymph node metastasis of primary malignant lung tumors and can indirectly predict the presence of lymph node metastasis through uptake in the primary lesions.
KOREAN JOURNAL OF RADIOLOGY
(2023)
Article
Oncology
Marc Moncrieff, Sarah Pywell, Andrew Snelling, Matthew Gray, David Newman, Clare Beadsmoore, Davina Pawaroo, Martin Heaton
Summary: This study confirms the increased accuracy of SPECT/CT for identifying SLN metastases, which appears to have a significant therapeutic benefit, although there is an increased risk of cancellation of the SNB procedure on the day of surgery.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Zeynep Eroglu, Kristy K. Broman, John F. Thompson, Amanda Nijhuis, Tina J. Hieken, Lisa Kottschade, Jeffrey M. Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K. Bartlett, Avinash Sharma, Lesly Dossett, Tasha Hughes, David E. Gyorki, Jennifer Downs, Giorgos Karakousis, Yun Song, Ann Lee, Russell S. Berman, Alexander van Akkooi, Emma Stahlie, Dale Han, John Vetto, Georgia Beasley, Norma E. Farrow, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, Michael Lowe, David W. Ollila, Frances A. Collichio, Roger Olofsson Bagge, Jan Mattsson, Hidde M. Kroon, Harvey Chai, Jyri Teras, James Sun, Michael J. Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi, Jonathan Zager, Nikhil Khushalani
Summary: Most patients with SLN+ melanoma no longer undergo a completion lymph node dissection (CLND) prior to adjuvant systemic therapy. The omission of immediate CLND in these patients may increase the risk of nodal relapse, but salvage surgery with therapeutic lymph node dissection (TLND) at relapse may be a viable option for these patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Katherine M. Marsh, Courtney M. Lattimore, Christopher L. Cramer, Craig L. Slingluff, Lynn T. Dengel
Summary: This study reports cases of primary melanoma draining to subcostal lymph nodes and provides characterization of the locations of these nodes. The study found that subcostal nodes are typically located under ribs 10-12 and have size limitations.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Ryusuke Nakamoto, Jialin Zhuo, Kip E. Guja, Heying Duan, Stephanie L. Perkins, Christoph Leuze, Bruce L. Daniel, Benjamin Lewis Franc
Summary: This study demonstrates the accurate localization of targets in the head and neck region using 3D augmented reality (AR) visualization of single-photon emission computed tomography (SPECT)/computed tomography (CT) data. The results show that wearing an AR headset significantly reduces the time required for target detection and provides high localization accuracy.
Article
Oncology
Kelsey B. Montgomery, Tanya A. Correya, Kristy K. Broman
Summary: The adherence to nodal surveillance ultrasound (US) remains unknown in real-world practice for patients with sentinel lymph node-positive (SLN+) melanoma. This study found that adjuvant therapy appears to be associated with a decreased likelihood of US adherence.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Cell Biology
Tiffany W. Cheng, Emily Hartsough, Alessio Giubellino
Summary: Assessment of sentinel lymph node status is crucial for melanoma patients' prognosis and therapeutic management, and pathologists play a vital role in this evaluation. Various methods have been used, including evaluating metastatic burden dimensions, determining tumor deposit locations within lymph nodes, and precise cell counting. However, no single method can independently predict prognosis. The management approach for sentinel lymph node-positive patients has also evolved, with a more conservative approach recognized for selected cases. This review provides an overview of past and current advancements in the field, along with potential future directions based on prior experiences and clinical trials.
Review
Oncology
Alessandra Ruenger, Dirk Schadendorf, Axel Hauschild, Christoffer Gebhardt
Summary: Clinical trials studying immune checkpoint inhibitors (ICIs) have excluded immunocompromised patients. This study reviewed the existing literature and analyzed treatment outcomes of 144 patients. The findings suggest that effective immunotherapy with retained transplant was achieved in approximately 30.8% of patients. The overall response rates of immunotherapy were similar to non-immunocompromised cancer patients, but publication bias may overestimate positive outcomes.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Microbiology
Philipp Jansen, Adelaida Creosteanu, Viktor Matyas, Amrei Dilling, Ana Pina, Andrea Saggini, Tobias Schimming, Jennifer Landsberg, Birte Burgdorf, Sylvia Giaquinta, Hansgeorg Mueller, Michael Emberger, Christian Rose, Lutz Schmitz, Cyrill Geraud, Dirk Schadendorf, Joerg Schaller, Maximilian Alber, Frederick Klauschen, Klaus G. Griewank
Summary: In this study, a machine learning algorithm was used to detect fungal elements on digitized histologic sections of human nail specimens, and its performance was compared with that of dermatopathologists. The results demonstrated that the algorithm achieved a comparable sensitivity to the human pathologists. This finding suggests that machine learning algorithms can serve as supportive diagnostic tools to improve the screening efficiency of fungal infections.
Article
Oncology
Lucas Schneider, Christoph Wies, Eva I. Krieghoff-Henning, Tabea-Clara Bucher, Jochen S. Utikal, Dirk Schadendorf, Titus J. Brinker
Summary: In this study, the contribution of different data types in a combined classifier for predicting BRAF mutation status in melanoma was analyzed. The multimodal classifier showed improved generalisability compared to individual classifiers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Alexander C. J. van Akkooi, Dirk Schadendorf, Alexander M. M. Eggermont
Summary: Sentinel lymph node biopsy (SLNB) was introduced in the 1990s to identify patients who may benefit from completion lymph node dissection. SLNB staging has been found to be the best for staging melanoma. Adjuvant systemic therapy and biomarkers are emerging, which might reduce the need for SLNB staging in the future.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Dermatology
Jan-Malte Placke, Delphine Mertens, Alpaslan Tasdogan, Eleftheria Chorti, Dirk Schadendorf, Selma Ugurel, Alexander Roesch, Ingo Stoffels, Joachim Klode
Summary: This study demonstrates that multispectral optoacoustic tomography (MSOT) can differentiate between benign and malignant lymphadenopathy by measuring the levels of oxyhemoglobin and deoxyhemoglobin in lymph nodes. It offers a noninvasive approach to avoid unnecessary lymph node biopsies and surgeries.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Infectious Diseases
Laven Mavarani, Sarah Albayrak-Rena, Anja Potthoff, Martin Hower, Sebastian Dolff, Stefanie Sammet, Felix Maischack, Dirk Schadendorf, Boerge Schmidt, Stefan Esser
Summary: Our study evaluated the changes in weight, body-mass-index (BMI), and waist-to-hip ratio (WHR) over a 5-year follow-up in people living with HIV (PLH) compared to the general population. The results showed that PLH had greater increases in weight and BMI after 5 years, but lower WHR change compared to the general population.
Article
Oncology
Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Rutkowski, Juergen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Munoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuan-Mai Couillebault, Helen Evans, Catarina D. Campbell, Sumit Basu, Michele Moschetta, Adil Daud
Summary: This study explores a targeted therapy for treating NRAS-mutant melanoma, showing promising antitumor activity in patients with the use of LXH254 and trametinib in combination.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Paolo Antonio Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina V. Long, Rachel E. Sanborn, Vanna Chiarion-Sileni, Brigitte Dreno, Stephane Dalle, Dirk Schadendorf, Margaret K. Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez-Roca, Naoya Yamazaki, Hussein A. Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob
Summary: Preliminary research shows that nivolumab and relatlimab have better efficacy in treating advanced melanoma patients who have previously received anti-PD-(L)1 treatment. The RELATIVITY-047 trial demonstrated that nivolumab and relatlimab, compared to nivolumab alone, significantly improved progression-free survival in previously untreated advanced melanoma patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen, Melissa Hamilton, Shien Guo, Ling Shi, Sarah Keidel, Georgina Long
Summary: The RELATIVITY-047 trial demonstrates that the fixed-dose combination of nivolumab plus relatlimab improves progression-free survival in patients with advanced melanoma while maintaining stable health-related quality of life. Although the combination treatment is associated with a higher incidence of severe adverse events, patients' discomfort with these events is low, supporting NIVO + RELA as a first-line treatment option.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Philipp Jansen, Daniel Otero Baguer, Nicole Duschner, Jean Le'Clerc Arrastia, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Joerg Schaller, Klaus Georg Griewank
Summary: In this study, a deep learning method was used to analyze histological tissue sections of melanoma patients, enabling accurate detection of lymph node metastasis and providing valuable reference for pathologists. The method was able to identify the size and classify the tumor, which is of great significance for prognosis assessment and treatment planning.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy, Katharina Schober, Markus V. Heppt, Imke von Wasielewski, Dirk Schadendorf, Ralf Gutzmer
Summary: The outcome of advanced melanoma patients has greatly improved over the past 15 years. Targeted therapies blocking BRAF or inhibiting immune checkpoints have shown significant efficacy in improving overall survival. The COMBI-r study confirms the efficacy of dabrafenib plus trametinib in routine clinical practice and provides additional data in patients with brain metastases or previous treatments.
Article
Oncology
Esmee P. Hoefsmit, Franziska Vollmy, Elisa A. Rozeman, Irene L. M. Reijers, Judith M. Versluis, Liesbeth Hoekman, Alexander C. J. van Akkooi, Georgina Long, Dirk Schadendorf, Reinhard Dummer, Maarten Altelaar, Christian U. Blank
Summary: Taking into account the higher response rates of neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma compared to stage IV disease, researchers hypothesized that systemic immune suppression may be responsible for lower response rates and disease recurrence. Through proteomic profiling, they found that the protein LRG1 is associated with worse prognosis and can serve as a biomarker for identifying high-risk patients and as a potential target for neoadjuvant ICB therapy.
CANCER RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Paolo A. Ascierto, Reinhard Dummer, Helen J. Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T. Flaherty
Summary: The purpose of this study was to evaluate the efficacy and safety of encorafenib alone or in combination with binimetinib for the treatment of advanced BRAF(V600)-mutant melanoma. The results showed that the combination of encorafenib and binimetinib improved progression-free survival and overall response rate, and had better tolerability compared to encorafenib alone.
JOURNAL OF CLINICAL ONCOLOGY
(2023)